Q1 2026 · 13F-HR
Redmile Group, LLCholdings as filed
Filed 2026-05-15 · accession 0001104659-26-062579
$1.51B
Reported value
35
Positions
2026-03-31
Period end
The Brief · Redmile Group, LLC · Q1 2026
AI · grounded in 13F
Redmile Group, LLC closed its position in RAPT for a reduction of $30.0M. The fund also exited its holding in REPL for $10.7M and established a new position in BMRN worth $9.8M. Additionally, the firm increased its stake in ALX ONCOLOGY HLDGS INC by 143.9% and XENE by 96.2%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $445.7M | 29.5% | 9,066,621 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $174.0M | 11.5% | 673,505 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $135.6M | 8.98% | 4,164,120 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $121.6M | 8.05% | 5,558,885 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $119.9M | 7.94% | 7,732,808 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $80.6M | 5.34% | 14,549,768 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $58.0M | 3.84% | 15,470,502 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO INC | $36.6M | 2.42% | 4,368,804 | Common | SOLE |
| 82024L103 | STTK | SHATTUCK LABS INC | $35.6M | 2.36% | 5,539,724 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $29.5M | 1.95% | 1,237,659 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $29.4M | 1.95% | 1,459,599 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $26.5M | 1.75% | 688,036 | Common | SOLE |
| 00091E109 | ABSI | ABSCI CORPORATION | $24.8M | 1.64% | 8,253,316 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $17.4M | 1.15% | 521,117 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $16.0M | 1.06% | 7,964,188 | Common | SOLE |
| 31189P102 | FATE | FATE THERAPEUTICS INC | $15.4M | 1.02% | 12,872,946 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $15.3M | 1.01% | 262,674 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $14.5M | 0.96% | 2,011,895 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $13.5M | 0.90% | 3,153,256 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $12.3M | 0.82% | 491,654 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $11.4M | 0.76% | 2,164,777 | Common | SOLE |
| 23306J309 | DBVT | DBV TECHNOLOGIES S A | $10.3M | 0.68% | 491,340 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $9.8M | 0.65% | 173,859 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $8.3M | 0.55% | 261,508 | Common | SOLE |
| 15678C102 | CBLL | CERIBELL INC | $7.1M | 0.47% | 386,786 | Common | SOLE |
| G5509L101 | LIVN | LIVANOVA PLC | $6.9M | 0.46% | 108,354 | Common | SOLE |
| G31249108 | ESTA | ESTABLISHMENT LABS HLDGS INC | $5.9M | 0.39% | 103,464 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $5.5M | 0.37% | 1,590,832 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $5.3M | 0.35% | 415,710 | Common | SOLE |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $5.1M | 0.34% | 700,000 | Common | SOLE |
| 039697107 | ARDX | ARDELYX INC | $4.4M | 0.29% | 733,350 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $3.4M | 0.23% | 2,648,659 | Common | SOLE |
| 046513206 | ATRA | ATARA BIOTHERAPEUTICS INC | $2.1M | 0.14% | 441,701 | Common | SOLE |
| 00860C102 | AGMB | AGOMAB THERAPEUTICS NV | $1.6M | 0.11% | 156,250 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $972,879 | 0.06% | 772,126 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.